Lexeo Therapeutics, Inc. · NASDAQ:LXEO

Lexeo Therapeutics — International Congress for Ataxia Research 2026

14 slides from Lexeo Therapeutics's conference presentation, Nov 11, 2026

  1. Slide 1: Safety and Preliminary Efficacy of AAVrh.10hFXN (LX2006) Gene Therapy in Friedreich Ataxia Cardiomyopathy

    Safety and Preliminary Efficacy of AAVrh.10hFXN (LX2006) Gene Therapy in Friedreich Ataxia Cardiomyopathy International Congress for Ataxia Research | November 11, 2026 Theresa Zesiewicz, Jonathan W. Weinsaft, Stephen M. Kaminsky, Aarti Patel, Ralitza H. Gavrilova, Susan Perlman, Udhay Krishnan, Mad

  2. Slide 2: Speaker Disclosures & Disclaimers

    Speaker Disclosures & Disclaimers Theresa Zesiewicz, MD, FAAN, Professor of Neurology Division Director, USF Ataxia Research Center; Co-Director, USF Movement Disorders Neuromodulation Center; Director, Frances J. Zesiewicz Parkinson's Disease Foundation • Principal investigator for ongoing trials s

  3. Slide 3: Cardiac Complications are the Leading Cause of Death in Friedreich Ataxia (FA)

    Cardiac Complications are the Leading Cause of Death in Friedreich Ataxia (FA) FA is a rare, progressive and devastating multisystem disease caused ~5,000 by a loss of function mutation in the FXN gene1. individuals affected by FA in the U.S.2 ~15,000 individuals affected by FA worldwide2 With a typ

  4. Slide 4: LX2006 Has the Potential to Treat the Root Cause of FA Cardiomyopathy

    LX2006 Has the Potential to Treat the Root Cause of FA Cardiomyopathy: The Significant Decrease in Frataxin in the Heart LX2006 construct: FA Cardiomyopathy FXN deficiency results in mitochondrial dysfunction and leads to deficient energy production in thickened cardiomyocytes FXN mutation Mitochond

  5. Slide 5: Lexeo's AAVrh.10 is a Highly Differentiated Capsid

    Lexeo’s AAVrh.10 is a Highly Differentiated Capsid Cardiac tropism of AAVrh.10 may allow lower doses for cardiac gene therapy PRECLINICAL DATA: Compelling cardiac tropism CLINICAL TRANSLATION: Significant evidence of protein with potential transduction in the PNS expression in LX2006 clinical data w

  6. Slide 6: LX2006 is Being Evaluated in Parallel SUNRISE-FA & Weill Cornell Trials

    LX2006 is Being Evaluated in Parallel Lexeo-Sponsored SUNRISE-FA & Weill Cornell Investigator-Initiated Trials 1 2 3 Study Design & Objective Key Inclusion Criteria Key Measurements Design: Adults Cardiac Structure & Function 52-week open-label study with a (18-50 years) (LVMI, hsTnI, other measures

  7. Slide 7: All Participants with Abnormal LVMi at Baseline: Sustained or Deepening Improvement Over Time

    All Participants with Abnormal LVMi at Baseline: Showed Sustained or Deepening Improvement Over Time Cardiac MRI: LVMi (n=6; abnormal at baseline) • Majority of participants reach or remain in 120.0 normal LVMi range at latest visit 110.0 • Durable LVMi improvement maintained out to three years foll

  8. Slide 8: All Participants (n=16) LVMi: Reached or Remained in the Normal Range at Latest Visit

    All Participants (n=16), LVMi: All Participants in Cohorts 2 & 3, Excluding Participant #10, Reached or Remained in the Normal Range for LVMi at Latest Visit LVMi (g/m2) for All Male Participants LVMi (g/m2) for All Female Participants 120 120 Participant 10(1) 110 110 100 100 90 90 LVMi (g/m2) LVMi

  9. Slide 9: Hs-TnI at Latest Visit (n=16): Reduced or Stable in Most Participants

    Hs-TnI at Latest Visit (n=16): Reduced or Stable hs-TnI Observed in Most Participants Biomarker: Hs-TnI (n=16) 100% increase from 100% baseline still below abnormal value 80% 60% Change from baseline (%) 40% • 16 of 17 participants have significantly Improvement 20% reduced or stable troponin I1 0%

  10. Slide 10: Cardiac Function Improvement Observed in Individual with Later-Stage Cardiomyopathy

    Cardiac Function Improvement Observed in Individual with Later-Stage Cardiomyopathy Cardiac Improvements 24 months Post LX2006 Treatment in Participant with Low Baseline LVEF Biomarker: High-Sensitivity Troponin I Cardiac MRI: LVMi 86% reduction 54% reduction 3000 120 hs troponin I (ng/L) 2500 100 L

  11. Slide 11: Beyond the Heart: Annual Mean Change From Baseline in mFARS With LX2006

    Beyond the Heart: Annual Mean Change From Baseline in mFARS With LX2006 4.0 Mean Change from Baseline (95% CI) 2.0 N=16 0.0 N=16 N=12* -2.0 N=7 -4.0 -6.0 -8.0 -10.0 Baseline 12 mo. 24 mo. 36 mo. mFARS, Modified Friedreich Ataxia Rating Scale. Notes: Data as of September 2026; *Participant #3 missed

  12. Slide 12: Beyond the Heart: Statistically Significant Improvement in Mean mFARS Scores

    Beyond the Heart: Statistically Significant Improvement in Mean mFARS Scores for LX2006-Treated Participants Compared to Propensity-Matched Control Cohort Change in mFARS (Total): Open-Label Cohort (n=16) vs. UNIFAI-Matched Control (n=44) ✓ mFARS validated clinical scale measures FA neurological pro

  13. Slide 13: Key Takeaways

    Key Takeaways Cardiac Remodeling Cardiac Function & Biomarkers Neurological Progression Hs-TnI was reduced or stabilized in LX2006 demonstrated a Sustained reductions in LVMi most participants, with improvement persisting neurologic effect via were observed in participants observed across multiple c

  14. Slide 14: Thank You!

    Thank You! Visit the Lexeo Therapeutics Table (Booth #305) to learn more about their FA program and other data presentations at ICAR 2026! 14

Lexeo Therapeutics — International Congress for Ataxia Research 2026 on 6ix